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Background: IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, leading to renal
failure in 15% to 40% of cases. IgAN is diagnosed by renal biopsy, an invasive method that is not risk-free. We used
blood and urine peptide profiles as a noninvasive method of linking IgAN-associated changes with histological
lesions by Oxford classification.
Methods: We prospectively studied 19 patients with biopsy-proven IgAN and 14 healthy subjects from 2006 to
2009, excluding subjects with crescentic glomerulonephritis and collecting clinical and biochemical data at the time
of diagnosis and during follow-up (24 months). Histological lesions were evaluated by Oxford classification.
Proteomic analysis was performed by combining magnetic bead (MB) technology and mass spectrometry (MALDI-
TOF MS) to obtain peptide profiles. Doubling of serum creatinine was considered a variable of poor renal prognosis.
Results: We identified 55 peptides—13 in serum, 26 in plasma, and 16 in urine—that differentiated IgAN patients
from healthy subjects. A significant association was noted between serum/plasma and urine peptides and
histological findings—ie, tubulointerstitial damage, segmental glomerulosclerosis, and endocapillary injury.
We also identified 3 peptides—corresponding to bradykinin, uromodulin, and alpha-1-antitrypsin—that were
associated with severity of lesions, such as tubulointerstitial damage and segmental glomerulosclerosis.
Moreover, blood peptides with m/z 2953, 5337, 9287, and 9289 and urine peptides with m/z 1769, 1898, 1913, 1945,
2491, 2756, 2977, 3004, 3389, and 4752 correlated significantly with poor renal function.
Conclusions: In patients with IgAN, the use of noninvasive approaches, such as blood and urine proteomics, can
provide valuable information beyond that of standard diagnostic techniques, allowing us to identify blood and
urine peptide profiles that are associated with poor histological lesions in IgAN patients.Background
IgA nephropathy (IgAN) is the most common primary
glomerulonephritis worldwide and is a significant cause
of renal disease, leading to end-stage renal disease
(ESRD) in 15% to 40% of patients after 20–25 years of
follow-up [1]. For this reason, methods must be devel-
oped to make an early diagnosis. Several clinical risk fac-
tors, such as male gender, hypertension, increased serum* Correspondence: ramon.romero@uab.es
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reproduction in any medium, provided the orcreatinine level, proteinuria >1 g/day, and absence of
hematuria, are associated with a poor prognosis [2]. Fur-
ther, histopathological findings at the time of diagnosis,
such as glomerulosclerosis and chronic tubulointerstitial
damage, are also predictors of poor renal outcome [3-5].
A diagnosis of IgAN is biopsy-proven, based on
pathological criteria that include the presence of dif-
fuse mesangial IgA deposits by immunofluorescence.
The Oxford classification is a recent histological
classification system that is based on 4 scores: inter-
stitial fibrosis/tubular atrophy (IFTA), segmental glo-
merulosclerosis, endocapillary hypercellularity, and
mesangial hypercellularity [6,7]. This new assessment
has demonstrated that each variable correlates with
clinical outcome [8,9].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sively to various fields of medicine, including nephrology
[10-15]—particularly in urine, because it can be obtained
noninvasively, allowing one to identify glomerular kidney
disease (GKD)-related markers [16-26]. Profiling methods
are gaining popularity in the quest for new putative bio-
markers for glomerular disorders [27-35]. Magnetic bead
(MB)-based fractionation methods, coupled with MALDI-
TOF MS, were introduced recently as a urinary peptide
profiling strategy [36-38] and have emerged as a suitable
platform for rapid, high-throughput analysis.
The main objective of our study was to identify
peptide profiles in blood and urine that are associated
with IgAN and its histological lesions.
Methods
Study population
This prospective study was performed between June 2006
and November 2009 in the Nephrology Department,
Germans Trias i Pujol Hospital (Barcelona, Spain). All
procedures were conducted per the Declaration of
Helsinki of 1971, as revised in 2008. The Clinical
Research Ethics Committee of Germans Trias i Pujol
Hospital approved the study protocol, and all patients
gave written informed consent to participate.
Study procedures
For inclusion, patients had to be aged older than 18 years;
show clinical signs of renal disease, such as proteinuria
with stable renal function or various degrees of renalTable 1 Demographic, clinical, and biochemical data of IgAN
At the time of
Number of patients
Age, years 42 (33
Gender (Male), n (%)
Hypertension (Yes), n (%)
Diabetes (Yes), n (%)
Dyslipidemia (Yes), n (%)
Serum creatinine, mg/dl 2.00 (1.4
Uric acid, mg/dl 7.40 (5.4
Serum albumin, g/l 34.00 (31.0
Cholesterol, mg/dl 194.00 (157.0
Proteinuria, g/24 hours 2.28 (1.2
RAAS blockade (Yes), n (%) 7 (3
ACEI 5 (2
ARB 1 (5
ACEI plus ARB 1 (5
Statins (Yes), n (%) 4 (2
Data are expressed as median and ranges. aSignificant Wilcoxon test (P < 0.05) in Ig
renin-angiotensin-aldosterone system; ACEI: angiotensin-converting enzyme inhibitfailure and the presence of hematuria; and be indicated
for renal biopsy. Only patients with primary IgAN were
included. Patients with crescentic glomerulonephritis
were excluded.
Healthy subjects were used as controls to establish a
normal peptide profile.
Measurement of clinical and biochemical parameters
The following clinical data were collected at the time of
diagnosis: age, gender, history of hypertension, diabetes
mellitus, and dyslipidemia. Biochemical data were col-
lected at the time of study and after 2 years of follow-up:
serum levels of creatinine, uric acid, albumin, and choles-
terol; and proteinuria. Statin therapy and antihypertensive
treatments that were based on renin-angiotensin-
aldosterone system (RAAS)-blocking drugs, such as
angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin II receptor blockers (ARB), were recorded
(Table 1).
Renal biopsy
Percutaneous renal biopsies were performed and
processed routinely for light, immunofluorescence, and
electron microscopy per standard procedures.
Light microscopy sections were stained with
hematoxylin/eosin, Schiff ’s periodic acid, methena-
mine silver, Masson trichrome, and Congo red.
At the time of the biopsy, a single pathologist
reviewed all renal biopsy slides and scored the patho-
logical variables per the Oxford classification as follows:patients
IgAN patients

















AN patients between the time of initial biopsy and the end of follow-up. RAAS:
ors; ARB: angiotensin II receptor blockers.
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segmental glomerulosclerosis absent (S0) or present
(S1); endocapillary hypercellularity absent (E0) or
present (E1); and mesangial hypercellularity ≤0.5 (M0)
or > 0.5 (M1) [6].
Blood samples
Blood samples were collected from the participants on
the same day that the renal biopsy was performed.
Serum and plasma-EDTA samples were obtained by
centrifugation at 2200 g for 10 min, aliquoted to avoid
freeze-thaw cycles, and stored at −80°C until use.
Urine samples
Fresh, first-morning urine samples were collected from
the participants on the same day that the renal biopsy
was performed. Briefly, urine samples were centrifuged
at 2100 g for 30 min at 4°C to remove particulate mater-
ial and cellular debris. The supernatant was adjusted to
6.5 pH with NH4HCO3 (1 M) to minimize precipitation
during storage, aliquoted to avoid freeze-thaw cycles,
and stored at −80°C until use [36]. Protease inhibitors
were not added. Normalization of the samples to urinary
protein concentration was not necessary to analyze
peptide profiles [38].
Peptide enrichment and identification by MALDI-TOF MS
analysis
Peptides in serum and plasma (80 μl) and urine super-
natant (110 μl) were extracted using MB. The profiling kit
that we used to analyze blood samples was the MB-IMAC
Cu kit (Bruker Daltonics, Bremen, Germany), which is
based on the affinity of peptides to immobilized copper
ions on the surface of MB. In the urine samples, the beads
that we used were coated with C18 aliphatic chains,
wherein peptides were captured by hydrophobic interac-
tions (DynabeadsW RP-C18, Invitrogen, the Netherlands).
Each serum, plasma, and urine sample was processed
in duplicate, and each duplicate was spotted twice on
the MALDI target (AnchorChip 600/384, Bruker
Daltonics). Thus, 4 MALDI spectra were obtained for
each sample, acquired for m/z values from 1000 to
10,000. ClinProTools (v2.0; Bruker Daltonics) was used
to analyze peptide profiles, subtract baseline values,
and normalize the spectra. Further details on the
MALDI-TOF MS analysis are described in our previ-
ous report [38,39].
Statistical analysis
Normality of the variables was assessed by Kolmogorov-
Smirnov test. Continuous variables were expressed as
median and range and were compared by Mann–Whitney
U-test or Kruskal–Wallis test, as appropriate. Wilcoxon
test was performed for paired samples as required toassess differences at the end of follow-up. Categorical vari-
ables were analyzed using chi-square or Fisher’s exact
probability test. Associations between variables were
assessed using the Spearman correlation coefficient.
Statistical analyses were performed using SPSS, v15.0
(SPSS Inc., Chicago, IL). A two-tailed p-value of <0.05
was considered to be statistically significant.
Results
Patients
Nineteen IgAN patients were enrolled, and 14 healthy
subjects were included in the study as controls. The
baseline clinical and biochemical characteristics of the
IgAN patients are summarized in Table 1. Healthy sub-
jects ranged in age from 26 to 41 years (median 30 years);
6 were male (43%). The entire control group had normal
renal function without hematuria or proteinuria, and
none was treated.
Significant differences were observed between IgAN
patients and healthy subjects with regard to age and
renal function but not gender. Also, we compared clin-
ical and biochemical variables at the time of biopsy with
those at the end of the follow-up (24 months) (Table 1).
During the follow-up, 5 patients (26.3%) with impaired
serum creatinine doubled their serum creatinine levels.
In contrast, proteinuria levels fell, albeit insignificantly.
Further, serum cholesterol and serum albumin levels
differed significantly between baseline and at the end of
the follow-up.
Identification of IgAN-related peptides in blood and urine
The blood and urinary peptide profiles of IgAN patients
differed significantly from those of healthy subjects;
using Clinprotools, we obtained 13 differential peaks in
serum, 26 in plasma, and 16 in urine that discriminated
IgAN patients from healthy subjects and achieved
statistical significance (Additional file 1). Two peaks in
plasma and 6 peaks in urine were identified in our
earlier reports [38,39].
Our results suggest that peptides that were detected in
plasma by MALDI-TOF at m/z = 1063 and m/z = 1898
correspond to bradykinin (KNG1) and complement factor
C4 (C4A), respectively [39]. Similarly, peptides that were
detected in urine by MALDI-TOF at m/z = 1898 and 1913
corresponded to uromodulin peptides (UMOD); those at
m/z = 1945, 2392, and 2505 corresponded to alpha-1-
antitrypsin peptides (A1AT); and that at m/z = 2714
corresponded to beta-2-microglobulin (B2M) [38].
Association between IgAN-related peptides and
histological lesions by Oxford classification
The histological lesions of the IgAN patients are
summarized in Table 2.
Table 2 Scores of histological lesions by Oxford
classification in IgAN patients





Segmental glomerulosclerosis, n (%)
S0 3 (16)
S1 16 (84)
Endocapillary hypercellularity, n (%)
E0 12 (63)
E1 7 (37)
Mesangial hypercellularity, n (%)
M0 0 (0)
M1 19 (100)
Interstitial fibrosis/tubular atrophy (IFTA).
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associated with IFTA lesions (Additional file 2). In evalu-
ating tubulointerstitial damage T2 (>50%) in patients
with IgAN, we noted that serum peptides at m/z 5966
and 9289 increased in peak area compared with the
other 2 groups (T0, T1). Moreover, serum peptides at
m/z 1466, 1617, 3193, 3264, 5337, 5889, and 5905
increased in peak area with respect to T1.
Similarly, plasma peptides at m/z 2661 and 2790 rose
in peak area versus the other 2 groups (T0, T1), but
plasma peptides at m/z 1063 and 1078 decreased in peak
area in IgAN patients with tubulointerstitial damage T2
compared with subjects with T0 and T1.
In urine, peptides at m/z 1945 and 2491 increased in
peak area in IgAN patients with T2 tubulointerstitial
damage (>50%), but peptides at m/z 1769, 1898, 2977,
3004, 3389, 3406, 4658, and 4752 fell compared with the
T0 and T1 groups. Further, as shown in Figure 1a-c,
bradykinin peptide (m/z 1063) and UMOD peptide (m/z
1898) decreased in parallel with the progression ofFigure 1 Differential expression of bradykinin, uromodulin, and alpha
(IFTA) lesion. Box plot of differential plasma expression of m/z 1063 (a) an
without (T0) or with (T1, T2) interstitial fibrosis/tubular atrophy (IFTA) lesiontubulointerstitial damage. But, A1AT peptide increased
proportionally to tubulointerstitial damage.
As shown in Figure 2a-d, urine peptides at m/z
1945, 2392, and 4013 increased in peak area in IgAN
patients with S1 lesions, but the peptide at m/z 3389
fell in peak area compared with IgAN patients with S0
lesions. No associations were observed between segmental
glomerulosclerosis and blood peptides.
A lack of endocapillary hypercellularity (E0) was asso-
ciated with increased peak areas of peptides at m/z 1546
and 3264, but the m/z 3242 peptide declined in peak
area in the serum of IgAN patients (Figure 3a-c). More-
over, E0 correlated with decreased peak area of peptides
at m/z 3242 and m/z 8602 in the plasma of IgAN
patients compared with endocapillary hypercellularity
(E1) (Figure 4a-b). No associations were observed in the
urine peptides.
No associations were observed between blood or urine
peptides and mesangial hypercellularity in IgAN patients.
Association between peptides and doubling of serum
creatinine in IgAN
Serum peptides at m/z 2953, 5337, and 9289 and plasma
peptides at m/z 9287 were linked with the doubling of
serum creatinine in IgAN patients. Also, urine peptides
at m/z 1769, 1898, 1913, 1945, 2491, 2756, 2977, 3004,
3389, and 4752 correlated with poor creatinine levels in
IgAN patients (Table 3).
Association between peptides and clinical parameters
Urinary UMOD-derived peptides (m/z 1898, 1913)
correlated inversely between baseline serum creatinine,
and m/z 1913 also correlated inversely with proteinuria.
Urinary A1AT-derived peptides (m/z 1945, 2392 and 2505)
showed a positive association with proteinuria. Also, m/z
1945 showed a positive correlation with serum creatinine.
Most patients had varying degrees of hematuria at diag-
nosis; thus, it was not possible to compare the influence of
hematuria on peptide profile changes.-1-antytripsin peptides by interstitial fibrosis/tubular atrophy
d urine expression of m/z 1898 (b) and m/z 1945 (c) in IgAN patients
s. Outliers are open circles. AU = Arbitrary units.
Figure 2 Differentially expressed peptide peaks in urine by segmental glomerulosclerosis lesion. Box plot of differential urine expression
of m/z 1945 (a), m/z 2392 (b), m/z 4013 (c), and m/z 3389 (d) in IgAN patients without (S0) or with (S1) segmental glomerulosclerosis lesions.
Outliers are open circles. AU = Arbitrary units.
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In this preliminary prospective study, peptide patterns in
blood and urine were observed in patients with IgAN that
allowed us to differentiate them from healthy subjects.
Bradykinin peptide and a fragment of complement C4a
were identified in blood samples, as were UMOD, A1AT,
and B2-microglobulin peptides in urine. Moreover, these
peptides were associated with poor histological lesions in
IgAN patients, particularly with tubulointerstitial damage
and segmental glomerulosclerosis.Figure 3 Differentially expressed peptide peaks in serum by endocap
expression of m/z 1546 (a), 3264 (b), and 3242 (c) in IgAN patients without
open circles. AU = Arbitrary units.In IgAN, much effort has been aimed to correlate a wide
range of histological lesions with clinical outcome. In this
report, we used the Oxford classification to explore IgAN-
associated changes from blood and urine peptide profiles,
because it is the most recent pathological classification
system and was developed as a reproducible method of
predicting the risk of disease progression with regard to
clinical outcome and histological lesions.
Recently, new methods have been described to identify
biological biomarkers in various fluids using proteomicillary hypercellularity lesion. Box plot of differential serum
(E0) or with (E1) endocapillary hypercellularity lesions. Outliers are
Figure 4 Differentially expressed peptide peaks in plasma by endocapillary hypercellularity lesion. Box plot of differential plasma
expression of m/z 3242 (a) and m/z 8602 (b) in IgAN patients without (E0) or with (E1) endocapillary hypercellularity lesions. Outliers are
open circles.
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that MB-based profiling and MALDI-TOF MS identify
disparities in urine between GKD patients and controls,
suggesting that establishment of a differential peptide
profile is the initial step toward classifying GKD. In the
current study, the majority of peptides, specifically high
levels of an A1AT-derived peptide (m/z 1945) and low
levels of a UMOD-derived peptide (m/z 1898) and brady-
kinin (m/z 1063), was linked to tubulointerstitial damage.
Alpha-1-antitrypsin protects the extracellular matrix
from neutrophil attack through its anti-inflammatory
and anti-apoptotic effects. Kwak et al. [40] reported
increased levels of A1AT peptides in kidney tissue and
urine in IgAN patients compared with healthy subjects.
The authors speculated that renal tubular epithelial cells
produce A1AT in response to tubulointerstitial damage.
Consistently, our results reinforce the suggestion that
high levels of A1AT in urine might constitute a responseTable 3 Relationship between doubling of serum
creatinine and peptide peaks
Biofluid Peptides (m/z) R p*
Serum 2953 0.624 0.040
5337 −0.615 0.044
9289 0.711 0.014
Plasma 9287 0.615 0.044
Urine 1769 −0.718 0.001








4752 −0.530 0.020to the inflammatory process in GKD. Likewise A1AT
has a function in tubulointerstitial injury; we noted an
inverse association between UMOD-derived peptides
and tubulointerstitial lesions, consistent with other
groups that have described low urinary UMOD levels in
association with tubular atrophy and interstitial infiltra-
tion in renal biopsies [41].
Uromodulin is a glycoprotein that is expressed on
renal tubular epithelial cells and is the most abundant
protein in urine. Recent studies have implicated UMOD
in chronic kidney disease [41-43]. In a previous report,
we observed an inverse correlation between UMOD
peptides, serum creatinine, and proteinuria in patients
with GKD [38].
Further, in IgAN, Wu et al. [37] described a urine pep-
tide profile, noting downregulation of peptide that
corresponded to UMOD, allowing them to discriminate
IgAN from healthy subjects. In the current study, our
peptide profile could be a biomarker of histological
lesions but is not specific for IgAN.
Rocchetti et al. [23] reported a significant decrease in
the urinary excretion of kininogen in IgAN patients,
particularly in unresponsive ACEI therapy patients. The
authors speculated that this difference reflects the sever-
ity of renal damage in IgAN patients. Similarly, we found
a decreased in kininogen-derived peptide bradykinin
(m/z 1063) in plasma from IgAN patients with severe
tubulointerstitial damage T2. But, we could not demon-
strate this effect because most patients did not receive
ACEI or ARB agents at baseline. Thus, we could not
compare the effects of these drugs on peptide profiles.
Bradykinin is a nonapeptide that is derived from
the kininogen protein, a robust agonist of the brady-
kinin 2 receptor, enhancing the production of nitric
oxide and prostaglandins. Potent renal vasodilator,
antithrombotic and antifibrotic effects of kinins have
been observed recently in diabetic nephropathy [44].
Furthermore, upregulation of bradykinin receptor has
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mental glomerulosclerosis [45].
In a previous report, Kang et al. [9] observed that
segmental glomerulosclerosis and IFTA reflect chronic
damage, which can be used to predict the long-term
prognosis of patients with IgAN. Our findings suggest
that a rise in peptides at m/z 1945, 2392, and 4013 and a
decline in the peptide at m/z 3389 observed in patients
with S1 reflect chronic glomerular injury.
Endocapillary and mesangial hypercellularity lesions
were not associated with renal outcome in the original
Oxford cohorts, although few reports have reported such
findings. In our study, we identified 5 peptides—in
serum at m/z 1546, 3264, and 3242 and in plasma at m/z
3242, 8602—of which the plasma and serum peptides at
m/z 3242 and plasma peptide at m/z 8602 increased and
serum peptides at m/z 1546 and 3264 decreased in the
presence of endocapillary hypercellularity.
Further, many IgAN patients showed mesangial
hypercellularity—this score is defined as the number of
mesangial cells per mesangial area. Previous studies
have shown that mesangial hypercellularity correlates
with an active lesion; perhaps patients with M1 have a
good response to treatment.
A limitation of this study is that we could not confirm
that peptides of bradykinin, UMOD and A1AT are
related specifically to IgAN, because our population was
in various stages of kidney disease and degrees of inter-
stitial injury. Interestingly, we found a relationship
between peptide profiles in the serum, plasma, and
urine of IgAN patients with the doubling of serum cre-
atinine levels—particularly, in the urine samples with
UMOD and A1AT peptides. Based on these findings,
we propose that this peptide profile is a potential
biomarker predictor of renal outcome, but we can not
exclude the possibility that these peptides constitute a
biomarker of chronic kidney diseases. It is necessary to
expand this population study to other types of GKD to
mitigate the limitations on its reproducibility and thus
obtain a specific peptide profile.
Similarly, our patients had mesangial hypercellularity,
and all were classified as M1. This feature of our study
population did not allow us to evaluate the influence of
this injury on peptide profiles. Finally, identifying
peptides in biological fluids is critical in determining
their function in the disease process.
Conclusions
IgAN is a glomerular disease, the pathogenic mechanism
of which remains unknown. Proteomic analysis allows us
to obtain a peptide profile that can enhance the diagnosis
and prognosis of this glomerular disease. Further studies
with more patients are needed to determine the functionof bradykinin, UMOD, and A1AT peptides in the patho-
genesis of IgAN.
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